Cannabinoid receptors and their endogenous agonists

被引:301
作者
Felder, CC [1 ]
Glass, M
机构
[1] Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery, Indianapolis, IN 46285 USA
[2] NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA
关键词
marijuana; anandamide; fatty acid ethanolamide; cannabinoids; receptors;
D O I
10.1146/annurev.pharmtox.38.1.179
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Marijuana has been in use for over 4000 years as a therapeutic and as a recreational drug. Within the past decade, two cannabinoid receptor types have been identified, their signal transduction characterized, and an endogenous lipid agonist isolated from mammalian tissues. The CB1 cannabinoid receptor is widely distributed in mammalian tissues, with the highest concentrations found in brain neurons. CB1 receptors are coupled to modulation of adenylate cyclase and ion channels. The CB2 receptor is found in cells of the immune system and is coupled to inhibition of adenylate cyclase. Both receptor types selectively bind Delta(9)-THC, the active principle in marijuana, and anandamide (arachidonylethanolamide), an endogenous cannabimimetic eicosanoid. Progress is being made in the development of novel agonists and antagonists with receptor subtype selectivity, mice with genetic deletion of the cannabinoid receptors, and receptor-specific antibodies, which should help in providing a better understanding of the physiological role of the cannabinoid receptors.
引用
收藏
页码:179 / 200
页数:22
相关论文
共 133 条
  • [1] ABERMAN J, 1997, S CANNABINOIDS, V1, P42
  • [2] Isolation and expression of a mouse CB1 cannabinoid receptor gene - Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells
    Abood, ME
    Ditto, KE
    Noel, MA
    Showalter, VM
    Tao, Q
    [J]. BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) : 207 - 214
  • [3] ADAMS IB, 1995, J PHARMACOL EXP THER, V273, P1172
  • [4] PHARMACOLOGICAL AND BEHAVIORAL-EVALUATION OF ALKYLATED ANANDAMIDE ANALOGS
    ADAMS, IB
    RYAN, W
    SINGER, M
    RAZDAN, RK
    COMPTON, DR
    MARTIN, BR
    [J]. LIFE SCIENCES, 1995, 56 (23-24) : 2041 - 2048
  • [5] BACHUR NR, 1965, J BIOL CHEM, V240, P1019
  • [6] Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides
    Barg, J
    Fride, E
    Hanus, L
    Levy, R
    MatusLeibovitch, N
    Heldman, E
    Bayewitch, M
    Mechoulam, R
    Vogel, Z
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 287 (02) : 145 - 152
  • [7] BARTH F, 1997, S CANNABINOIDS, V1, P11
  • [8] DRONABINOL AS A TREATMENT FOR ANOREXIA ASSOCIATED WITH WEIGHT-LOSS IN PATIENTS WITH AIDS
    BEAL, JE
    OLSON, R
    LAUBENSTEIN, L
    MORALES, JO
    BELLMAN, P
    YANGCO, B
    LEFKOWITZ, L
    PLASSE, TF
    SHEPARD, KV
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (02) : 89 - 97
  • [9] Functional role of high-affinity anandamide transport, as revealed by selective inhibition
    Beltramo, M
    Stella, N
    Calignano, A
    Lin, SY
    Makriyannis, A
    Piomelli, D
    [J]. SCIENCE, 1997, 277 (5329) : 1094 - 1097
  • [10] Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells
    Bisogno, T
    Sepe, N
    Melck, D
    Maurelli, S
    DePetrocellis, L
    DiMarzo, V
    [J]. BIOCHEMICAL JOURNAL, 1997, 322 : 671 - 677